Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib Monotherapy and in Combination With Azacitidine in MDS After HMA Failure
NCT02721875Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of volasertib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Apr 2016; status: terminated.
02
Drugs
volasertib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02721875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721875.